CJC-1295 No DAC / Ipamorelin Blend

CJC-1295 No DAC / Ipamorelin Blend Combination Synergy Profile

The CJC-1295 No DAC / Ipamorelin Blend is specifically designed to bypass single-receptor limitations, forcing a synchronized biological cascade across multiple distinct physiological pathways for exponential results.

Pharmacological Composition

Parameter	Value
Composite Ratio	Mod GRF (1-29) + Ipamorelin
Molecular Complex Output	Mixed Sequence
Synergistic Purity	Clinical Grade Ratio
Appearance	White-to-off-white solid

Figure 1: Cross-Pathway Receptor Action of the Blend

Dual / Tri-Phase Transduction Pattern

Detailed cascade of actions highlighting the compound synthesis:

1. Synthesizes the absolute synergy between a GHRH (Growth Hormone Releasing Hormone) and a GHRP (Growth Hormone Releasing Peptide).
2. CJC-1295 No DAC physically opens the somatotroph 'gate' at the anterior pituitary.
3. Ipamorelin simultaneously triggers the massive 'pulse' of endogenous Growth Hormone release.
4. This perfectly mimics the natural, pulsatile physiological rhythm of human GH secretion.
5. Bypasses the suppression of somatostatin (the body's 'stop' signal for GH).

Figure 2: Multiplicative Rate of Synergistic Recovery / Output

Primary Research Results

• Synergy 1: The most sought-after anti-aging specific combination to safely maximize sustained IGF-1 numbers.
• Synergy 2: Produces absolutely zero spikes in cortisol or prolactin (unlike older GHRPs like GHRP-6 and GHRP-2).
• Synergy 3: Significantly deepens Slow Wave Sleep (SWS) immediately upon injection.

The Gold Standard GH Secretagogue Combination

The CJC-1295 No DAC (Mod-GRF 1-29) / Ipamorelin blend is the most widely used growth hormone secretagogue combination in research, representing the synergy between GHRH receptor activation and GHS-R1a (ghrelin receptor) activation. These two receptors converge on pituitary somatotrophs through complementary signaling pathways: Mod-GRF activates Gs/cAMP/PKA while Ipamorelin activates Gq/PLC/IP3/Ca2+. The simultaneous engagement of both pathways produces GH pulse amplitudes 3–5 times greater than either peptide alone.

1. Mod-GRF binds the GHRH receptor, raising intracellular cAMP and activating PKA-mediated GH gene transcription and vesicle priming.
2. Ipamorelin simultaneously binds GHS-R1a, activating PLC and releasing calcium from intracellular stores, triggering the actual vesicle exocytosis event.
3. The combination mimics the natural dual-input system: hypothalamic GHRH primes somatotrophs, and ghrelin triggers the release—the peptide blend replicates both inputs artificially.
4. Ipamorelin’s unique selectivity means no cortisol, prolactin, or appetite stimulation accompanies the amplified GH pulse.
5. The resulting GH pulse closely matches physiological nocturnal GH surges in both magnitude and kinetics.

Research Protocol Considerations

• GH Amplification: Individual GH peaks of 5–15 ng/mL from each peptide alone are amplified to 30–60 ng/mL when co-administered, demonstrating true pharmacological synergy.
• Clean Profile: Ipamorelin’s selectivity makes this the “cleanest” GH secretagogue combination available—no significant cortisol, prolactin, or appetite perturbation.
• Pre-Blended Convenience: Single-vial formulation ensures the correct 1:1 peptide ratio and eliminates the need to reconstitute and draw from two separate vials.
• Timing: Administered before bedtime on an empty stomach to amplify the nocturnal GH pulse. Some protocols add a morning dose for twice-daily GH pulsing.
• Dosing: Each injection provides 100 μg Mod-GRF + 100 μg Ipamorelin. 1–3 doses daily. Reconstitute with BAC water; refrigerate after reconstitution.